Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review

The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannelos, Nikolaos, Ng, Cheryl, Curran, Desmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Zoster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054181/
https://www.ncbi.nlm.nih.gov/pubmed/36916240
http://dx.doi.org/10.1080/21645515.2023.2168952
_version_ 1785015606088564736
author Giannelos, Nikolaos
Ng, Cheryl
Curran, Desmond
author_facet Giannelos, Nikolaos
Ng, Cheryl
Curran, Desmond
author_sort Giannelos, Nikolaos
collection PubMed
description The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs.
format Online
Article
Text
id pubmed-10054181
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-100541812023-03-30 Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review Giannelos, Nikolaos Ng, Cheryl Curran, Desmond Hum Vaccin Immunother Zoster The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs. Taylor & Francis 2023-03-14 /pmc/articles/PMC10054181/ /pubmed/36916240 http://dx.doi.org/10.1080/21645515.2023.2168952 Text en © 2023 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Zoster
Giannelos, Nikolaos
Ng, Cheryl
Curran, Desmond
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
title Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
title_full Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
title_fullStr Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
title_full_unstemmed Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
title_short Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
title_sort cost-effectiveness of the recombinant zoster vaccine (rzv) against herpes zoster: an updated critical review
topic Zoster
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054181/
https://www.ncbi.nlm.nih.gov/pubmed/36916240
http://dx.doi.org/10.1080/21645515.2023.2168952
work_keys_str_mv AT giannelosnikolaos costeffectivenessoftherecombinantzostervaccinerzvagainstherpeszosteranupdatedcriticalreview
AT ngcheryl costeffectivenessoftherecombinantzostervaccinerzvagainstherpeszosteranupdatedcriticalreview
AT currandesmond costeffectivenessoftherecombinantzostervaccinerzvagainstherpeszosteranupdatedcriticalreview

Ejemplares similares